Feature | May 14, 2012

Implantable Defibrillators Fine for Use in Athletes

Yale study shows ICD restrictions for athletes may not be necessary

May 14, 2012 – A study of more than 350 competitive athletes with implantable cardioverter defibrillators (ICDs) from around the world showed for the first time that sports may be safer for this group than has been thought. There were no occurrences of death or injury due to arrhythmia or shock during sports in this group.  Additionally, only 10 percent of the athletes received a shock during competition or practice and of those, most continued to play, as reported at the Heart Rhythm Society (HRS) scientific sessions in Boston.

These results are based on a prospective study, the international ICD Sports Safety Registry.  This study is the first of its kind to offer tangible evidence about the risks of sports activity in athletes with ICDs, empowering physicians to evaluate sports participation on a case-by-case basis. Currently, consensus statements recommend restriction of competitive sports for all athletes with an ICD because of the unknown risks. 

“We did not know if defibrillation would work during sports…The body works differently during sports activity,” said Rachel Lampert, M.D., FHRS, lead author of the study and associate professor of medicine at Yale University School of Medicine.

“The answer to this was zero — there were no injuries,”

There was concern adrenaline and trauma, especially to the ICD leads, might cause the devices to malfunction. The registry followed 372 athletes from around the world for more than 2.5 years. The ages of the patients ranged from 10 to 60. About 70 percent of patients received shocks during the registry, including 30 during sports activity.

“People were getting shocked, but they were appropriate and the defibrillators worked during the sports activities,” Lampert said.

Even though people were shocked during sports, she said most athletes continued with the sport.

“These data suggest that the blanket statement that all vigorous competitive sports be restricted for patients with ICDs may not be necessary. Yet, it by no means suggests that all ICD patients should be playing sports,” said Lampert.  “We believe this continues to reinforce the importance of informed and thoughtful discussions between physicians and patients, and provides new information that will help guide the final decision on whether it is safe for an individual to participate in a competitive sport with an ICD.”

The purpose of an ICD is to convert all episodes of ventricular fibrillation (VF) or ventricular tachycardia (VT) through a defibrillation shock to the heart.  Because the effectiveness of the ICD during the stressful conditions of intense sports was previously unknown, sports have not been recommended.  But, the true risks have also not been known.

The study evaluated the primary endpoints of 1) death or resuscitated arrest or 2) injury during sports due to arrhythmic symptoms and/or shock.  Secondary results that were monitored included system malfunction and incidence of ventricular arrhythmias (VA) requiring multiple shocks for termination.  No primary endpoints occurred and of the secondary results, only ten percent of the athletes were shocked during competition or practice.  Lead malfunction rates were similar to those reported previously for ICD patients leading the authors to conclude “these data do not support competitive sports restriction for all athletes with ICDs.”

The median age for participants in the study was 33, with ages ranging from 10 to 60.  The most common sports were running, basketball and soccer.  Athletes were recruited through physician sites and patient advocacy groups and all were already involved in competitive (n=328) or dangerous (n=44) sports.

For more information: www.HRSonline.org

Related Content

Biotronik, FDA, MR Conditional CRT devices, Iperia HF-T, defibrillator, ProMRI
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 03, 2016
Biotronik announced U.S. Food and Drug Administration (FDA) approval of Iperia ProMRI HF-T, a cardiac resynchronization...
AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
microtubules, heartbeat mechanics, Perelman School of Medicine study

Microtubules in a cardiomyocyte at rest (top) and when compressed. Image courtesy of the lab of Ben Prosser, Ph.D., Perelman School of Medicine, University of Pennsylvania

News | EP Lab| April 29, 2016
Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact...
Boston Scientific, FDA, ImageReady MR-Conditional Pacing System
Technology | EP Lab| April 28, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for...
Feature | Business| April 28, 2016 | Dave Fornell
 
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
post-operative atrial fibrillation, AFib, heart rate, rhythm control, ACC.16
News | Atrial Fibrillation| April 20, 2016
In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following...
St. Jude Medical, EnSite Precision cardiac mapping system, European release
Technology | EP Mapping and Imaging Systems| April 19, 2016
St. Jude Medical Inc. announced expansion of its EnSite Precision cardiac mapping system limited market release in...
cardiac arrest, out-of-hospital, antiarrhythmic drugs, New England Journal of Medicine Study, ACC.16
News | Sudden Cardiac Arrest| April 19, 2016
April 19, 2016 — Researchers have confirmed that certain heart rhythm medications, when given by paramedics to patien
St. Jude Medical, SJM, MultiPoint Pacing, CRT, cardiac resynchronization therapy, U.S. launch
Technology | Cardiac Resynchronization Therapy Devices (CRT)| April 18, 2016
St. Jude Medical Inc. announced the U.S. launch and first U.S. implants of the Quadra Assura MP cardiac...
Overlay Init